where experts go to learn about the FDA
FDA Law Blog where experts go to learn about FDA
Hyman, Phelps & McNamara, P.C.
Menu
Menu
  • Practices
  • Industries
  • FDA Regulatory Categories
  • Professionals
  • About Us
  • Contact
  • LinkedIn
  • Twitter
FDA Law Blog
News & Events
  • LinkedIn
  • Twitter
  • Recent Posts
    • To Meet or Not to Meet: Day 70 and Counting July 18, 2025
    • Blood Pressure Rising: FDA Warning Letter Takes an Aggressive Approach on General Wellness Product July 17, 2025
    • CMS Proposals Would Raise the Bar on Bona Fide Service Fees for Average Sales Price July 16, 2025
    • ACI’s Annual Legal, Regulatory, and Compliance Forum on Cosmetics & Personal Care Products – West Coast Edition July 15, 2025
    • Federal Hiring Shake-Up (Again): What the Latest Executive Action and Supreme Court Decision Mean for Industry July 14, 2025
  • Trackers
    • 180-Day Exclusivity Tracker
    • FDA Citizen Petition Tracker
    • REMS Tracker (Historical – Not Recently Updated)
    • FDA Legislation Tracker
  • Orange Book Archives

     

    ANDA Paragraph IV Patent Certifications List Archives

  • Scorecards
    • Generic Drug Labeling Carve-Out Scorecard
    • Biosimilars State Legislation Scorecard (Historical – Not Recently Updated) 
  • Blogroll
    • Big Molecule Watch Blog
    • Bloomberg BNA Health Care Blog
    • Drug and Device Law Blog
    • Eye on FDA
    • FDA Matters
    • Harvard Law Bill of Health
    • IN VIVO Blog
    • Internet Drug News.com
    • Lachman Consultants Blog
    • Medical Devices Today
    • Orange Book Blog
    • The Orange Book Insights Blog
    • Pharma IQ
    • Pharmalot
    • SCOTUS Blog
    • The Volokh Conspiracy
    • WLF Legal Pulse
  • Resources
    • Centers for Medicare & Medicaid Services
    • Drug Enforcement Administration
    • Food and Drug Administration
  • Categories
    • Advertising and Promotion (Federal Trade Commission)
    • Advertising and Promotion (OPDP)
    • Animal Drugs and Feeds
    • Biosimilars
    • Cannabis
    • cGMP Compliance
    • Consumer Product Safety Commission
    • Controlled Substances
    • Cosmetics
    • COVID19
    • Current Affairs
    • Dietary Supplements
    • Drug Development
    • Drug Enforcement Administration
    • Enforcement
    • FDA News
    • Foods
    • Foods and Dietary Supplements
    • Fraud and Abuse
    • Government Pricing
    • Hatch-Waxman
    • Health Care
    • Health Privacy
    • Import/Export
    • In Vitro Diagnostic Devices
    • Jobs
    • Medical Devices
    • Miscellaneous
    • Orphan Drugs
    • OTC Drugs and Cosmetics
    • Prescription Drugs and Biologics
    • Product Jurisdiction and Combination Products
    • Reimbursement
    • Tissue Products
    • Tobacco
    • Uncategorized
  • Your search for “Cotizacion de seguros para autos Sonoma CA llama ahora al 888-430-8975 Responsabilidad civil seguro automotor Del seguro contra robos de autos Aseguradora plan seguro Como funciona el seguro de automovil Seguros por meses de coches Seguros coche baratos” returned the following results.

    For the Love of Money: The Trump Administration’s Fiscal Year 2018 FDA Budget Plan

    …approval and administrative actions can and should pay more to support FDA’s continued capacity. The Fiscal Year 2018 Budget includes $5.1 billion in total resources for FDA, which, with the…

    Small Change: FDA’s Final Predetermined Change Control Plan (PCCP) Guidance Ditches ML and Adds Some Details, But Otherwise Sticks Closely to the Draft

    …agrees the review can be achieved in real-time) De Novo 510(k): Traditional and Abbreviated Unfortunately, the final guidance continues to exclude Special 510(k)s (see our prior blog post here). In…

    Days Go By* – Particularly When Responding to an FDA Inspection

    …15 business days to address. Regardless of whether the company can complete activities by the time the initial 483 response is due, or simply sets forth its plan for how…

    GAO Report Confirms the Obvious: Food Safety Has Been Driving the Bus at FDA’s FVM Program

    …all of the FVM Program’s strategic objectives. In addition, GAO notes that the Strategic Plan as yet lacks an implementation plan that would lay out “specific actions, priorities, and milestones”…

    CMS Proposes to Require WAC Disclosure in TV Ads for Rx Drugs

    …is relatively straightforward. Any advertisement on TV (including broadcast, cable, streaming, or satellite) for a prescription drug or biological would have to contain the following statement: The list price for…

    FDA’s Pre-Cert Program Enters its Testing Phase

    …here, here, and here). In January of this year, FDA released version 1.0 of Developing a Software Precertification Program: A Working Model (Working Model) and an accompanying Software Precertification Program:…

    Florida Proposes Plan to Import Drugs from Canada

    …Care Administration (AHCA) to establish a Canadian Prescription Drug Importation Program and an International Prescription Drug Importation Program. Florida Governor Ron DeSantis signed the bill into law on June 12,…

    CDRH’s Plan to De-risk the Medical Device Valley of Death

    …scope of the TAP Pilot. Id. All in all, we think the TAP Pilot has the potential to be a valuable program and we applaud the Agency for including performance…

    FDA Releases Report on Rare Diseases and Accelerating the Development of Therapies for Pediatric Rare Diseases

    …studies and other clinical trials for investigational drugs in PRD population Device strategies Develop expedited approval pathway for certain devices intended to treat unmet medical needs Evaluate the results of…

    FDA Flexes New Enforcement Muscle; Issues Warning Letter for Failure to Meet Required Postmarketing Study Milestone Dates

    …“3-month pancreatic safety study in a diabetic rodent model treated with sitagliptin.”  FDA documented the agreement in approval letters (here and here) with the following timetable: Final Protocol Submission: June…

    Pfizer Reaches Record Settlement with Feds; Yes, That Is $2.3 Billion with a ‘B’

    …Second, on the civil side, Pfizer has agreed to pay $1 billion in civil settlements of cases which were brought under the federal False Claims Act (“FCA”) by whistleblowers (called…

    Allergan Settles with DOJ Related to the Sales and Marketing of BOTOX

    …no criminal or civil charges were brought against individuals in this case. Notably, the Allergan press release mentions that the Government required Allergan to dismiss its First Amendment case, in…

    The FTC Resurrects Its Penalty Offense Authority in a Big Way

    Last fall, when AMG Capital Management, LLC v. FTC was pending before the Supreme Court, former Federal Trade Commission (FTC) Commissioner Rohit Chopra (now Director of the Consumer Financial Protection…

    Second Bill to Curb Underage Dextromethorphan Abuse Introduced in House

    …the sale of dextromethorphan to individuals under 18 years old.  Senator Robert Casey (D-Pennsylvania) introduced a companion bill, S. 644, the Preventing Abuse of Cough Treatment Acts of 2013, (also…

    DOJ Files Criminal Case Against Vascular Solutions, Inc. for Off-Label Device Promotion

    …forum shopping starkly contrasts with “the old days” when FDA criminal cases were almost always brought in the company’s principal place of business.  This trend is troubling for companies because…

    Page 11 of 57« First«...101112...2030...»Last »

    Search FDA Law Blog

    Subscribe

    Never miss a post from FDA Law Blog







    Latest Tweets

    Tweets by @fdalawblog

    Awards & Honors

    • Best Lawyers in America® – 2025
    • Ranked in Chambers USA – 2024
  • Recent Posts
    • To Meet or Not to Meet: Day 70 and Counting July 18, 2025
    • Blood Pressure Rising: FDA Warning Letter Takes an Aggressive Approach on General Wellness Product July 17, 2025
    • CMS Proposals Would Raise the Bar on Bona Fide Service Fees for Average Sales Price July 16, 2025
    • ACI’s Annual Legal, Regulatory, and Compliance Forum on Cosmetics & Personal Care Products – West Coast Edition July 15, 2025
    • Federal Hiring Shake-Up (Again): What the Latest Executive Action and Supreme Court Decision Mean for Industry July 14, 2025
  • Trackers
    • 180-Day Exclusivity Tracker
    • FDA Citizen Petition Tracker
    • REMS Tracker (Historical – Not Recently Updated)
    • FDA Legislation Tracker
  • Orange Book Archives

     

    ANDA Paragraph IV Patent Certifications List Archives

  • Scorecards
    • Generic Drug Labeling Carve-Out Scorecard
    • Biosimilars State Legislation Scorecard (Historical – Not Recently Updated) 
  • Blogroll
    • Big Molecule Watch Blog
    • Bloomberg BNA Health Care Blog
    • Drug and Device Law Blog
    • Eye on FDA
    • FDA Matters
    • Harvard Law Bill of Health
    • IN VIVO Blog
    • Internet Drug News.com
    • Lachman Consultants Blog
    • Medical Devices Today
    • Orange Book Blog
    • The Orange Book Insights Blog
    • Pharma IQ
    • Pharmalot
    • SCOTUS Blog
    • The Volokh Conspiracy
    • WLF Legal Pulse
  • Resources
    • Centers for Medicare & Medicaid Services
    • Drug Enforcement Administration
    • Food and Drug Administration
  • Categories
    • Advertising and Promotion (Federal Trade Commission)
    • Advertising and Promotion (OPDP)
    • Animal Drugs and Feeds
    • Biosimilars
    • Cannabis
    • cGMP Compliance
    • Consumer Product Safety Commission
    • Controlled Substances
    • Cosmetics
    • COVID19
    • Current Affairs
    • Dietary Supplements
    • Drug Development
    • Drug Enforcement Administration
    • Enforcement
    • FDA News
    • Foods
    • Foods and Dietary Supplements
    • Fraud and Abuse
    • Government Pricing
    • Hatch-Waxman
    • Health Care
    • Health Privacy
    • Import/Export
    • In Vitro Diagnostic Devices
    • Jobs
    • Medical Devices
    • Miscellaneous
    • Orphan Drugs
    • OTC Drugs and Cosmetics
    • Prescription Drugs and Biologics
    • Product Jurisdiction and Combination Products
    • Reimbursement
    • Tissue Products
    • Tobacco
    • Uncategorized
  • Copyright 2025 FDA Law Blog HPM
    • Disclaimer
    • Careers